Flotek Industries, Inc. (FTK) Earnings Call Transcript & Summary
November 17, 2020
Earnings Call Speaker Segments
Danielle Allen
executiveThanks, and good morning to all of you. We're glad you could join us. On the line with me today are John Gibson, our Chairman, Chief Executive Officer and President; Michael Borton, our Chief Financial Officer; TengBeng Koid, President of Global Business; and Ryan Ezell, President of Chemistry Technologies. We'll begin today's call by offering prepared comments about our business and the results for the quarter. After that, we'll take whatever questions you have. Our earnings announcement for the third quarter went out yesterday, and you can find it on our website. This call is being webcast, and a replay will be posted on our website as well. Please keep in mind that anything we say today about projections or what we expect for future events counts as forward-looking statements. Such statements carry a number of risks and uncertainties, and many of those lie outside our control. Actual results could differ materially from what we currently expect because of these risks and uncertainties. We encourage listeners to look over our earnings release and the risk factors covered in our SEC filings. In addition, please see the reconciliations included in our earnings press release, since management might discuss non-GAAP metrics on this call. With that said, I'll hand things over to John.
John Gibson
executiveThank you, Danielle, and I want to express my appreciation to all of you — our team members, the people who invest in us, those we serve, and the members of our Board of Directors. The tremendous backing Flotek has gotten makes me deeply thankful. On top of that, our staff truly inspires me; day in and day out they've stayed dedicated and concentrated on bringing our vision to life, all while balancing shifting responsibilities at home and on the job, a mix of varying back-to-school arrangements, and ever-changing hurdles tied to the pandemic. There aren't words strong enough to convey how thankful I am for their commitment, and working beside them is a tremendous privilege. Before we go further into the quarter, I'd like to extend a welcome to Mike Fucci, who is joining Flotek's Board of Directors. Mike, who previously served as Chairman of Deloitte, U.S., is a highly admired and impactful leader whose career has been devoted to shaping the strategic direction of one of the globe's most esteemed professional services and accounting organizations. Beyond that, throughout his professional life, Mike has established himself as a leading voice on human capital, diversity and inclusion, and business transformation; having Mike with us is a real stroke of good fortune. Mike, I appreciate you coming aboard Flotek's Board; I'm genuinely eager to collaborate with you; so now, let's move on to the third quarter. Taken as a whole, our performance for the quarter revealed a few encouraging signs, yet we are in no way content with what we delivered, and additional effort lies ahead. As I mentioned three months ago, steering our way through this worldwide market upheaval brought on by COVID and the collapse in demand has been the toughest set of conditions I've ever faced in my professional life. Even with all that, my outlook on Flotek's future remains highly positive. We are pulling out all the stops to put ourselves in position to come out of this as a more robust company in 2021; that requires having the resolve to take certain tough steps right now. During the prior quarter, you got introduced to Mike Borton, our new CFO, on just his third day at Flotek; and from that point on, each day he has been hard at work pinpointing opportunities for us to boost business performance, tighten up our processes, bring in efficiencies, and carry out cost reductions. Mike's meticulousness and dedication to high standards keep making a strong impression on me. I'm delighted that he's part of the team. Alongside the leadership group, Mike has pushed forward a number of key initiatives that, though painful in the present, mean we come out of this stronger down the road as the market bounces back. That covers an impairment, write downs on inventory, and cuts to the workforce; what we're in is a transitional stretch. Our view is that the leadership group now in place is the right one to help push the company's transformation ahead faster, and we are making the changes our business model requires. The culture we're creating is one that generates value for every shareholder — entrepreneurial in spirit, with chemistry serving as the shared platform, and grounded in dedication to customer success and returns to shareholders. Flotek has a plainly defined route to growth and profitability, and results are what our team is concentrated on. Turning now to the broader macro picture, let's take that up first, since it has been the unavoidable force weighing on how our business has performed. Even though the world began gradually coming out of COVID lockdowns during Q3, conditions in the oil and gas sector are still under serious strain. A sharp decline in oil and gas activity across the board heavily constrained customer CapEx work from the wellhead all the way to the gas pump, with many projects paused and certain locations shut down entirely. On top of that, midstream budgets along with gathering and processing are down 60% compared with a year earlier, and American motorists cut their driving mileage by roughly 34%, which brought a matching decline in refined fuel use. That being said, certain encouraging signals are still visible. Crude prices have started improving relative to the prior quarter, though they remain at depressed levels. Refinery throughput is up, yet margins stay squeezed and customer demand hasn't risen in step. A number of customers have restarted limited completion work in the Permian, and we experienced stronger demand for our specialty chemical offerings — stimulation chemicals especially — in certain international markets, mainly the Middle East. To sum up, the market showed modest gains, but nowhere near enough to justify enthusiasm that a recovery is underway. Consequently, the quarter proved tough, with results that were mixed. Faltering economic activity and soft demand are pressuring sales throughout our business segments. During the prior quarter, we finalized our purchase of JP3, a data and analytics technology firm that serves the oil and gas industry. With JP3's results now part of our financials for the first full quarter, its performance came in far below what we had expected, since JP3's sales suffered from steep cuts to capital budgets among midstream and downstream customers. Given those circumstances, we examined closely what was realistically achievable near term; considering the expected continuing market upheaval and the resources required to shift toward a recurring revenue model; and having finished that review, we determined an impairment charge should be recorded across multiple categories for JP3; we likewise finished our quantitative and qualitative inventory analysis after the acquisition to evaluate market values and the anticipated customer demand. At the same time, we are cutting operating expenses to match the revenue decrease we expect from the move to a recurring subscription model and from softer demand in a challenging market; these cost cuts involve a 35% headcount reduction in that segment, plus lower other operational costs that aren't tied directly to near-term revenue generation; these steps weren't easy to make, but they were required as we run the business in a way that limits the effect on our liquidity in 2021 and afterward while we shift toward subscription based revenues. I'm also happy to share that TengBeng Koid has taken on the role of President of JP3. We brought Koid to Flotek during the previous quarter, after he accumulated over 30 years of experience in the oil and gas industry. This individual has a demonstrated ability to lead, creating software solutions used company-wide by energy firms spanning the entire hydrocarbon chain, and he has shown a remarkably solid history of taking businesses into global markets. My confidence in Koid and everyone on the JP3 team to create an exceptionally bright future is complete. Looking further ahead, there are substantial chances for growth in this business; we continue to feel assured regarding the attractive strategic and financial upside as JP3 takes Flotek's operations into every part of the hydrocarbon value chain, and its technologies assist customers in speeding up digital transformation through delivery of the real-time information needed to oversee crude oil and natural gas processing. There is also a chance for us to tackle potential greenhouse gases alongside JP3, so emerging markets represent a genuine opportunity for us too. Gordon will discuss the shift toward a subscription-based data model and will also point out our plan for growth aimed at broadening market penetration, at home and overseas. Moving on to chemistry technologies and the sanitizer and disinfectant operation we recently started, which we'll frequently call the JanSan business. During the quarter, we faced pricing pressure because suppliers offering lower-quality goods gave state discounts in order to clear out inventory before the expected tightening of regulatory standards, which we think will push such products out of the market; we believe these disruptions will only last a short while. Despite the recent news regarding expected COVID vaccines, we still think consumer and business behavior will shift over the long run. Getting shots made, produced, distributed, and given to large numbers of people is going to take a while, and there's still a lot we don't know about how many people in America will agree to take one when there's no data yet on how well it works over the long run or what side effects it brings. The main thing I'd like to emphasize is that inside JanSan we're building out a product portfolio. It stretches beyond sanitizer to cover more of what the janitorial and sanitizer market needs, and it extends past the current pandemic. Broadly speaking, our chemistry technology segment posted sequential improvement as activity in energy chemistry strengthened, both domestically and abroad. So we're pleased to share that total segment revenue for the third quarter came in 52% higher than in the second quarter. Now let's turn to how we're handling liquidity and expenses. Guided by our strategic pillars, we continue making bold moves to set Flotek up as well as possible for what lies ahead. Our balance sheet remains in good shape, and we're focused on building greater financial flexibility. Keep in mind that to protect our liquidity earlier in the year, we reduced our workforce, cut pay for the executive team, scaled back discretionary spending, and reduced what our Board of Directors receives. Throughout the quarter, we continued working alongside suppliers to negotiate raw material pricing, obtained lower lease terms, and reduced what we pay for freight. At this point I'll pass it to Koid, who can share more on JP3's revenue-generation work. After that, we'll hand things over to Ryan Ezell, and he'll provide an update on what's happening with the chemistry technology segment, covering how our new JanSan operations are progressing. Koid?
Teng Beng Koid
executiveAppreciate that, John. Like John said, even though the market gave us some tough sledding, we took advantage of that stretch to speed up our plan for breaking into the global marketplace, reshaping how we do business, and zeroing in on specific uses for our transformative technology. When it comes to going global, JP3 previously only covered North America. Back in September, we brought aboard an experienced business development executive for the Middle East to assist us in boosting JP3 adoption across the Middle East, Africa and Asia. From that point on, we've had lots of substantive discussions, gotten extremely positive responses from prospective clients, and we're now answering numerous RFPs. Though selling overseas takes more time, we feel good about the possibilities across the mid to long-term, and we're getting ready to roll out our technology into this market; that's truly thrilling. Number two, we're shifting and speeding up our business away from conventional equipment sales toward the subscription-based model; over the long-term, this will deliver the most value for JP3's customers as well as our shareholders. Even as we keep a certain amount of equipment-based contracts in place to meet what customers need, we're making an aggressive move toward subscription-based contracts, which will boost our recurring revenue. On top of that, we keep nurturing solid ties with current clients while forging new ones to grow our customer base. Take, for instance, our close collaboration with Phillips 66 — during the second quarter, we entered into a collaborative agreement with them. Under this arrangement, we'll deliver a data services offering designed to optimize transmix, which refers to the natural blending that happens between neighboring batches of differing fuels moving through a shared pipeline. This offering delivers real-time data, allowing quicker decisions that help cut down on transmix and lift profitability for refined fuel producers, transporters and terminal operators. It's heartening to witness such strongly positive responses regarding the worth of this partnership, and it confirms the strength and value our customers are experiencing through our one-of-a-kind technology. We're eager to see this application gain broader adoption in the market; with that, I'll hand the call over to Ryan Ezell so he can talk about our chemistry technologies. Ryan?
Ryan Ezell
executiveAppreciate that, Koid. One quick note before I dive in: within our chemistry technology segment, we include both the energy chemistry technologies and the more recently added janitorial and sanitizer operations, and I take considerable pride in our teams, who are executing their responsibilities effectively. I'll begin with news about the janitorial supply operation, which goes by JanSan. Last quarter, we introduced Flotek's FDA-grade hand sanitizer product line, targeting industrial as well as consumer markets. That initial move came about through community outreach that kicked off in the first quarter, when we started producing and giving away hand sanitizer to communities close to us, first responders, hospitals, schools, homeless shelters, and senior residential communities. Following that, we identified an opportunity to expand our business-to-business revenue into a reinvigorated sector possessing significant growth prospects, one that arose organically from what we know in specialty chemistry. Leveraging our technical — our capabilities in chemical manufacturing, along with ISO certified plants, we applied our globally recognized research and development resources to produce an expanding range of premium goods registered with both the FDA and EPA. Currently, we are engaged in active sales of janitorial and sanitizing items that carry FDA and EPA registration, serving numerous sectors including hospitals and medical facilities, the travel and hospitality industry, food services, ecommerce and retail, sports and entertainment, and additional industrial and consumer markets. By introducing surface-cleaning disinfectants alongside what we already sell in hand sanitizers, we could give the JanSan sector—particularly commercial and industrial users—a fully rounded lineup. Following a robust second quarter, our hand sanitizer segment faced some headwinds during the third quarter. Since appetite for hand sanitizing items had climbed so steeply, a wave of newcomers rushed into the market, often bringing raw materials of poor quality or ones that were actually contaminated. More lately, with the FDA expected to restore its earlier, stricter quality requirements, those opportunistic makers of inferior hand sanitizer have been offloading stock onto the market as they leave the business, throwing off the equilibrium between supply and demand. John mentioned that we see this interruption as short-term. Even more significantly, purchasers today are getting better informed and understand that regulatory compliance is necessary to provide the high-quality item that Flotek delivers. Consequently, we are beginning to observe customers purchasing our hand sanitizer repeatedly, along with greater emphasis from commercial and institutional buyers on metrics measuring product quality. What we saw during the second quarter—those triage <<inaudible>> buys—is now shrinking back toward standard purchasing procedures, and in our view, surplus inferior inventory ought to start clearing out of the marketplace. Flotek currently sells in 25 states, and compared with the prior quarter, we've grown our distribution customer base by 28% and our end use customer base by 49%. On top of that, our goods are now available for purchase directly by consumers through Amazon. What we hear back from buyers has been encouraging and steady; within the JanSan sector, Flotek's offerings rank among the finest technologies available, and our demonstrated strengths in supply chain and logistics set us apart from competitors. To build something durable and capable of lasting, we're expanding how we reach customers, and we've grown our JanSan lineup to include disinfectant wipes and sprays, surface cleaners and degreasers, along with manufacturing partnerships involving emerging technologies in the JanSan space. Another thing I'm happy to report is that our new packaging line has allowed us to boost our capabilities further, cut costs, and shorten the time it takes to finish orders. A great deal of opportunity lies ahead in our view, especially within JanSan, and our outlook on these over the long run is positive. Since we have the ability to keep expanding what we're capable of, we'll put money into marketing people and resources who bring solid distribution and sales backgrounds so that our ties in the JanSan marketplace grow stronger. Our JanSan effort shows the way we adjust and shift resources toward high growth operations that ought to generate favorable returns; and we're eager to share more updates as we move forward in this thrilling market; now let me turn to a couple of remarks regarding our energy chemistry business, about which, first of all, I want to say it's getting better, and I'd like to offer some key points on that front; and while industry analysts have noted drops in chemistry consumption and contracting chances hurt by M&A dealings, certain macro forces are assisting in pushing energy chemistry ahead. Because demand started surpassing output toward the close of the third quarter, completion and fracing work gradually trended higher, and we've observed certain clients raise their use of our specialty chemistries when their completion work picked back up, owing to better production and the return on invested capital that our products provide. Actually, during a recent trip to see one of our biggest customers, Flotek earned strong commendation for the robust partnerships we've established, built on a steadfast commitment to reliably supplying our chemistries, technical support services, and well-site implementation. On top of that, I'm encouraged by our chances abroad, which are creating gains for our energy chemistry business. Within the Middle East, we've been designated the Chemical Partner of Choice to supply a wide array of cold tubing stimulation additives to a significant NOC via collaboration with end market and international service companies. This prospect, along with others, ought to fuel our expansion in the Middle East as we look ahead over time; additionally, as Mike will cover in more depth, we've kept up our emphasis on cutting costs and enhancing the supply chain, which includes managing inventory and streamlining our finished goods count, producing better efficiencies throughout our business. To wrap up, I want to stress that as of today our energy chemistry business is genuinely a transformed business. Throughout the last 12 months, we have reduced what it costs us to operate, gone back to the table on our logistics and supplier agreements, and sped up efficiency gains across our business processes; what we ended up with is a leaner company, one able to serve what the oil and gas industry requires now and going forward, and we bring something distinctive and worthwhile to the market, specifically; first, providing chemistry solutions that are cost effective; second, engineering and executing optimized chemistry; and third, assisting operators in raising production while lowering the cost per barrel produced. Looking toward 2021, our attention is on bringing Flotek back to the market, and strengthening ties with our customers who are active and successful so that our global market share grows. With that said, I'll hand the call over to Mike Borton, who will go through our financial results.
Michael Borton
executiveThank you, Ryan, and good morning to all of you. From the time I came aboard Flotek in early August, my attention has been squarely on assessing how solid the books are — the balance sheet, the way we count things, how we prioritize spending, what we've committed to on the expense side, and how we handle our cash — while also trimming the number of banking relationships we maintain and putting in time with the new auditors. Over my first three months with Flotek, I've begun putting several strategic priorities into place that will assist us in building a stronger organization. On top of that, drawing on what I learned at a number of technology companies earlier in my career, where we managed to move successfully to a recurring revenue model, we have reworked the financial framework and the underlying assumptions for JP3 going forward. We need to make certain JP3's structure is optimized so that the cash required is kept to a minimum as we shift to a new model, under which we recognize revenue over a span of years, or else at the moment of installation. What this means is that upfront cash outlays for inventory will be necessary, requiring more cash than a one-time product sale would, with consequences for revenue as well as cash. That being said, JP3 is carrying sufficient inventory to push back the actual cash outlays in the near term. Let me stop here to stress the upside of moving to a subscription-based revenue model: it produces a recurring revenue stream with higher margins over a longer horizon, along with higher multiples, because of its predictability. In brief, as John pointed out, we are making, and will keep making, the business decisions required to keep our cash usage to a minimum. First, allow me to discuss the impairment we reported this quarter for JP3. As we work through the lingering effects of COVID-19, together with the ongoing drop in oil and gas demand and spending budgets, particularly in the refinery and the mid and downstream markets, we booked a goodwill impairment charge of $11.7 million and an intangible asset impairment charge of $12.5 million; an independent valuation company and the auditors worked alongside us to complete these adjustments. Second, we seized the chance to review our inventory throughout the company. For the last several months, I've been collaborating with our new and highly capable VP of Supply Chain, Shane Wise. That effort has led us to adopt new policies and rationalize a substantial share of our inventory by cutting hundreds of underperforming product SKUs. As a result, in the third quarter we took excess of obsolete reserves of $9.6 million. This charge has two components; the first is the reserve of $5.7 million, tied to the chemistry technology segment, and $3.9 million for JP3. Beyond that, while assessing inventory after the JP3 acquisition, the company found measurement period adjustments amounting to $2.3 million that were applied to the initial purchase price accounting. I want to stress that every one of these adjustments is one-time in nature, and because of these steps, we are in a better position to manage our inventory position and profitability going forward. Then, regarding the terms of the purchase agreement for the JP3 acquisition, along with the earnout conditions tied to Flotek stock performance: during the third quarter, the company booked a liability amounting to $2.5 million. That payment went into the escrow account in early October to satisfy the acquisition terms. This $2.5 million escrow transfer takes the place of the 3 million shares previously held in escrow; those shares went out to JP3 shareholders during the fourth quarter. I want to point out that provisions now exist along with a shift in the fair value estimate, we are not taking into account any acquisition purchase price adjustment, so Flotek recorded $3.2 million in charges that hit operating income in the third quarter; we also want to remind everyone that during the second quarter we altered our reporting technology — methodology, stemming from the JP3 acquisition, and we now present results across two new reportable segments: chemistry technologies and data analytics. What was formerly called the energy chemistry technology segment is now the chemistry technology segment, and it now encompasses our recently launched janitorial and sanitizer operations that Ryan just walked through. The data analytics business came about alongside the JP3 acquisition. Also, keep in mind, our third quarter results represent the first full quarter to include JP3's business operations and expenses. Earlier discussion of our financial performance goes into greater detail. As John said before, we dealt with a difficult third quarter caused by persistently weaker global demand and industry pressures, which affected both of our segments. Turning to the income statement: in the third quarter, consolidated revenue came to $12.7 million, a 43.5% increase over $8.9 million in the second quarter, while falling short of the $21.9 million posted during the same period a year ago. That sequential gain came mainly from a pickup in energy chemistry activity, since demand recovered both domestically and in international markets following the second quarter dip. The steep year-over-year revenue drop stems largely from ongoing volatility in the macro environment for onshore drilling and completion activity, which political and economic events in foreign markets have impacted. Additionally, COVID-19 hurt our productivity because of reduced customer demand for our services and products, apart from our sanitizer operations, which only recently ramped up in the second quarter of 2020. Consolidated operating expenses reached $29.5 million in the third quarter of 2020, rising 24.47% over last year's level of $23.6 million in the third quarter. Setting aside those one-time adjustments of $9.7 million of inventory and $3.2 million of acquisition-related expenses, we were pleased to report that expenses fell nearly 30% year-over-year. Corporate G&A dropped $3 million to $2.7 million versus $5.7 million last year, thanks to a reduction in overall compensation spending, lower discretionary spending, including professional fees, partially offset by one-time severance charges. Our depreciation and amortization expenses fell $1.5 million to $500,000 in the third quarter versus $2.1 million last year. In the third quarter, R&D expenses came to $1.5 million, a bit under the $1.6 million we saw in the second quarter, and lower than the $2.3 million recorded a year ago; for the third quarter of 2020, we posted a loss from continuing operations of $45.2 million, which works out to $0.66 loss per diluted share, versus a loss of $11.2 million, or $0.19 loss per diluted share, a year earlier. EPS took a negative hit of $0.36 from the JP3 impairment, $0.14 from inventory rationalization, and JP3 continued consideration of 5%. Those three one-time items accounted for the vast majority of the total record loss per diluted share. Adjusted EBITDA for the third quarter showed a loss of $6.5 million, an improvement from the $8.2 million loss last year. That better adjusted EBITDA is likely the result of lower expenses, as discussed earlier. Now, turning to how the balance sheet performed. Like John said earlier, our cash position is still healthy, and preserving our liquidity is a priority. At the close of the third quarter, cash and equivalents stood at $49.1 million, compared with $59.9 million in the second quarter. As has been fully disclosed, the company and JP3 together had $5.7 million in loans outstanding under the Paycheck Protection Program. As noted before, managing our inventory position is an absolute priority. In the quarter, inside the chemistry technology division, we cut SKUs by 35% as we work to manage inventory efficiently. We project that SKU reduction will generate yearly savings exceeding $1.3 million in inventory carrying costs. I'll hand the call back to John now for some closing comments.
John Gibson
executiveThank you, Mike. Let me take a moment for some closing thoughts. Back in January, when I came to Flotek, I set out several strategic goals for growth: cutting our reliance on rig count, growing new product lines that generate more backlog and/or revenue that recurs annually, setting our offering further apart from rivals while boosting our ability to deliver digital transformation of chemistry, and reinforcing our market share in the product lines we already have. Of course, at that point none of us could have predicted just how severely the market would be upended. Even so, we've adjusted our business while keeping our focus on carrying out that strategy, which remains valid even in a market like this. And though it's far from where I want us to be on progress right now, we are moving forward and building a solid base for 2021 and past that. To begin, we're dedicated to protecting our liquidity and keeping our balance sheet healthy. We're lucky to have Mike here at the company to help us hold onto our capital and to help foster a culture devoted to the leanest possible cost structure while still providing outstanding customer service. We're creating a more varied source of income. By acquiring JP3, we're broadening our business and giving downstream, midstream and upstream customers access to distinctive digital transformation of products and services. There's also potential for us to bring this offering into the greenhouse gas and ESG segments, and we're looking into that, while simultaneously examining all of this digital transformation to build a recurring revenue model for us. On top of that, by launching our janitorial and sanitizing products along with logistic services, we've diversified further beyond hydrocarbon markets into industrial and consumer markets. Operationally speaking, we have unsold manufacturing capacity available in the chemistry technology business for both energy and JanSan products, along with the capabilities to deploy toward the most appealing market opportunities. Without adding much extra cost, we've come up with additional products that can genuinely assist us on the revenue side and Flotek. We also see a significant set of international opportunities across all our businesses in the oil and gas focused products, encompassing both JP3 and the energy chemical technologies, where we expect to see far less volatility going forward compared with domestic markets. So we're quite pleased that we've already expanded into the international segment. To wrap up, chemistry is what we do best. We've built three robust business labs focused on generating value from chemistry. Though it's hard to say when the world will get back to normal, we're implementing the right measures and investments so that in 2021 and beyond we come out as a stronger company ready for the future with optionality. There's still plenty of work ahead and we're dedicated to it. Now I'll hand it back to you for some questions. Thanks very much.
Joseph Von Meister
analystHey, everyone. Could you share what hand sanitizer revenue looked like during Q3, and where you'd hope that line of business stands 12 months from now?
John Gibson
executiveI'll take that first part. We aren't providing a separate figure, since our aim was really to hold onto some edge over rivals in the market; that said, I'd describe the result as depressingly below my expectations, and quarter-over-quarter we saw no growth, largely for the reason Ryan gave earlier — many players flooded the market with sanitizer, and as that period began, sanitizer was our main focus. Yet across the past 3 months, we've broadened that lineup so we can function as a genuine JanSan participant, since buyers in that space want a portfolio of products rather than a single-item purchase. Ryan, chime in.
Ryan Ezell
executiveYou're right about that. To drive the point home, John, our initial commercial sales and the JanSan <<inaudible>> operation actually started through our philanthropic work, and within just a few weeks of being involved there, we came to understand — while evaluating what would make a viable business over the long haul — that we had to cover the entire portfolio, not merely the hand sanitizers and the different dispensable formats, but also the complete service market surrounding those products within JanSan, which in total is far bigger than hand sanitizer alone. That's the moment we expanded into numerous categories: surface disinfectants, sprays, wipes, degreasers, cleaners — everything tied to our core chemistry competency at Flotek, and none of it creates any strain for us in making that shift. We've rolled out a significant product line in that space since then and are seeing solid traction. What's emerging now are the building blocks of repeat customers on longer-term agreements with set monthly orders, which is exactly what we're aiming for on the sustainability side of the market.
Joseph Von Meister
analystThen, regarding JP3 — I realize the pipeline and refinery teams have faced considerable strain — but how do things look for the Phillips 66 joint venture, and what business opportunities stem from it?
Teng Beng Koid
executiveAlright, I appreciate that question. As for our partnership with Phillips 66: by way of that introduction, we were brought in front of a fairly large group of prospective clients. A good number of them have moved forward, and from what I gather, one has actually reached the proposal stage. So I'd say the worth generated by deploying this technology for that transmits <<inaudible>> is enormous. The feedback has been encouraging, and we expect some favorable outcomes before long.
John Gibson
executiveAnother aspect I appreciate regarding our position with JP3 and cohort leadership is that we see a fairly broad array of possibilities in the international market. That said, we're exercising some caution and forecasting when we'll be able to reach those, since we're still obtaining all the certifications and registrations needed for international markets. You can't simply ship there and break any U.S. law. So we're being very specific, and there are laws tied to shipping fiber, and fiber involves different links, plus encryption connected to any of the models we might place on the chip. So we're proceeding carefully, we see a path forward and it's clear. So I expect that we'll be able to report back on that and JP3 <<inaudible>>.
Joseph Von Meister
analystAppreciate it, everyone. Honestly, you did a strong job given how difficult that quarter was.
John Gibson
executiveThank you, Joseph.
Daniel Burke
analystAlright, let me start. John, I've got a question for you, and then another one about JP3. When it comes to how the business performed in Q3, it possibly fell a bit short of what you originally expected. I suppose I'm just trying to get a clearer picture of whether that's because the severity of the COVID-related effects on that business's end markets was underestimated, or whether it's really more tied to the shift toward a subscription-based model, which is taking longer to pull off, or proving somewhat harder to pull off, than maybe was expected before. Could you walk me through that?
John Gibson
executiveWell, Daniel, you deserve some kind of prize for such a perceptive question. I was extremely bullish on JP3. After we bought it, I believed COVID would die down far faster than it actually has. So we did miss what we'd assumed the projections would be for the rest of the year. But the main reason is that we couldn't get to customers, and we couldn't get to sites. Even lately, while attempting an installation for a sale, one of our employees had a COVID-related exposure, and that stopped us from completing the install right away; so these tags ran into operational problems. So COVID, I'd attribute 80% of the shortfall to that. Another chunk of what we're missing comes from the way our sales team is changing — moving from pushing hardware to pushing subscriptions, which has turned out to be harder, even though the team is handling it fairly well. Over here in the U.S., we added a new salesperson. Her whole professional history was in delivering subscription based models, and she is completely on board. Honestly, she's one of my favorite people to talk with, given how excited she gets about what we'll be capable of doing. Then there's a second international salesperson that Koid recruited, quite similar, and both of them carry a subscription based background, so they know how to position it and how to sell it. Another thing on our list is moving folks who previously purchased hardware over to a subscription arrangement, and that effort is already in motion. Honestly, going back and doing this proved tougher than we'd anticipated — largely a COVID effect, though it's also true that certain customers simply prefer having the equipment as their own. Where that leaves us: we don't have full certainty. That uncertainty even carried into the go-forward projections that fed into the impairment. As for how the mix breaks down — well, it's hard to lay that out cleanly for you. There are certain nations where we might be obligated to provide hardware first, followed by maintenance contracts. From a subscription standpoint, we'll need to walk you through how that works, since rules will dictate whether those countries are permitted to access cloud-based offerings. The regulatory landscape differs from one country to the next. So while we have some knowledge to build on, my enthusiasm is high. James Silas has joined us here. We discussed this topic a bit earlier. When it comes to the future of monitoring greenhouse gases, my excitement couldn't be greater, and I'm also thinking about whether we should incorporate sensors. James, what are your thoughts on that?
James Silas
executiveAbsolutely, John. At the moment, we're looking into what choices we have for fresh ways of detecting things, and the capabilities that the current JP3 system offers won't be something we can take advantage of. Plus, with the addition of new sensors along with modeling techniques, there's real excitement on our side about what could become possible in satisfying those needs that are emerging within the market.
John Gibson
executiveDo you have another one for us, Daniel?
Daniel Burke
analystYep, I'm here. That was really useful, John. The next thing I wanted to ask is probably simpler. Could you give us either a sense of timing, or if that's harder, the revenue top line you're expecting now, given the cost cuts you've made this year — what's your current view on how high that top line has to be for us to move nearer to an EBITDA breakeven level? Thanks.
John Gibson
executiveWell, part of why Mike is here is that he never stops taking costs out, so the top line keeps shrinking. That remains our focus, and we have to stay relentless, because sadly, I don't have an answer for you; and the reason there's no answer is that uncertainty is still so great that once I look past Q4, my picture of how the market is recovering starts to blur. I expected COVID to have faded, and it didn't. In fact, it's rising again in the northern hemisphere, so that's hitting us once more. We're aware of vaccines, yet this management team has no enthusiasm for them at this point, largely because a great deal remains uncertain — when will they be available? What quantity will be available? How will distribution work? So as for our forecasts, I'll simply say we're going to work extremely hard, but I can't predict as precisely as I'd want to. What I can do is control cost aggressively, and that's where our attention must be in the short term.
Daniel Burke
analystThat's reasonable. Fine, then. Okay, everyone, I'll stop here. Appreciate the time.
Michael Borton
executiveThank you, Daniel.
Eric Swergold
analystMorning, everyone. Three things I'd like to ask, and none of them connect to the others. First off, will the chargers you absorbed during this quarter leave us with NOLs that shield future profits? And could you put a number on that?
John Gibson
executiveI'll let Mike handle that one.
Michael Borton
executiveSo the main factor here is timing. You're likely aware that entering 2020, we had approximately $50 million in NOLs. Those came with a 20-year carryback and could be used at 100%. In 2020, the positive side is that tax losses from that year will rise indefinitely, though they can only be utilized at 80%. Now let's turn to the inventory write-downs. We aren't able to claim the tax benefit from those until the inventory is actually disposed of. Still, our aim is to move that inventory out fast. That's because you want the cash. Whatever amount we're able to realize is tied to the write-downs, and at that point it would become a tax benefit.
Eric Swergold
analystAll right. My next question concerns the JanSan line — will that carry the Flotek name, a private label, or a mix of the two?
John Gibson
executiveEric, I'll kick things off and then hand it to Ryan to wrap up. The short answer is yes. We examined what our chemical production capabilities allow, whether that's energy chemistry like the CNF products, or disinfectants, sanitizer, and surface cleaners. From our standpoint, that comes down to capacity, and our aim is to reach the fullest possible utilization of that capacity for blending sand chemicals. So regardless of whether the work serves the energy business or the JanSan business, it turns out the labor is identical, the facilities are identical, the equipment is identical, and our assets are about the same — we did alter a small piece so we could obtain FDA registration. The efficiency is such that everything we do on the JanSan side adds strongly to our overall chemistries, revenues and profitability. Still, our plan is to pursue whatever generates profit for our shareholders. Ryan?
Ryan Ezell
executiveBuilding on what John said, I’ll fill in a bit more. What we’re examining is this: we put substantial money into a fast-moving study looking at which paths made the most sense for Flotek on the commercial side—industrial and institutional purchasers—compared with the retail channel, plus how cost-effective each approach would be for us. Essentially, what we observe is that moving into commercial, whether institutional or industrial, fits squarely with our strengths: getting product delivered through our logistics, our expense base, our ability to capitalize on supply and cost benefits, and reaching the market. That involves a mix of what we’d call private manufacturing, white labeling, and building the Flotek name, since institutional purchasers care deeply about EPA and FDA compliance—an area where we excel. As we gain a foothold in that space, we believe our ecommerce operations can serve as a kind of practice ground for training and brand growth, which should eventually let us create a more powerful Flotek brand within possible retail operations. Yet all of that has to be weighed against the reality that going straight after retail demands a big marketing spend. So those are among the main reasons we prefer the commercial markets—all that upfront spending, and the balance between private contracting and building the Flotek brand among institutional buyers.
Eric Swergold
analystThanks a lot; and now for the third question, which isn't connected to the others — this call has been really informative up to this point, but — at a recent industry conference, Flotek shared some fresh data about a new and improved CNF product line that was producing results, and I can't recall the percentage of additional lift it was achieving compared with your earlier product. But are you seeing any initial signs of how customers are responding to this newer, better product?
John Gibson
executiveDr. Silas?
James Silas
executiveAbsolutely, I’m glad to talk about that. It had to do specifically with a few customers we’re looking at in the Midland basin. Drawing on what we know and have done in that region, we suggested a few minor adjustments and tweaks involving the CnF product line. What we’re seeing with it makes us very pleased. We believe that customer is happy with it, since they’re using that specific product, and we’re eager to bring it to additional customers in that area too. Once again, this reflects our knowledge and experience in reservoir-based chemistry being put to work.
Eric Swergold
analystExcellent, many thanks. Best of luck out there, everyone.
John Gibson
executiveThanks.
John Gibson
executiveAlright, let me wrap this up and say where things stand. Normally I wouldn't offer any guidance at all, yet right now I'll provide a little bit of Q4 macro environment guidance; domestically in the U.S., we've witnessed quite a bit of consolidation. That's among the reasons I feel enthusiasm about growing abroad. NOCs <<inaudible>> in those markets typically don't join together with reduced volatility. So staying committed to an international footprint matters a great deal to us. However, that could perhaps decelerate certain possible sales we have during Q4, simply because during consolidation folks often stop paying attention to their operational ball. Number two is that holidays are approaching. Thus COVID becomes a justification to head home early and stop spending whatever remains of your capital budget. So certain customers of ours might disappear from Thanksgiving all the way through January 7. And last, COVID is resurging. So although we remain here, giving it our all daily, I'd say Q4 will mostly reflect industry activities, and I'm not truly excited about it, yet I'm not depressed about it either. We have the right things underway, we're speaking with the right customers. In just a few days I depart on a trip across Oklahoma and Texas to meet customers we're eager to talk with and describe what we do. But how fast does that convert into revenue? COVID worries me, the holidays worry me, and consolidation worries me, since it involves some of our better customers. With that, thank you very much. We truly appreciate you, guys. Our focus entirely is on getting some returns for shareholders, and so we'll stay at it. Have a good holiday, and we'll talk soon.
Operator
operatorThat brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Flotek Industries, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Flotek Industries, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Flotek Industries, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.